Northern Trust Corp Has $3.01 Million Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Northern Trust Corp raised its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 2.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 991,043 shares of the biopharmaceutical company’s stock after buying an additional 26,248 shares during the period. Northern Trust Corp owned 0.95% of Revance Therapeutics worth $3,013,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in RVNC. Natixis acquired a new position in shares of Revance Therapeutics during the fourth quarter worth $31,000. Two Sigma Securities LLC acquired a new position in shares of Revance Therapeutics during the fourth quarter worth $35,000. Alpine Global Management LLC acquired a new position in shares of Revance Therapeutics during the fourth quarter worth $37,000. RPO LLC acquired a new position in shares of Revance Therapeutics during the fourth quarter worth $55,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Revance Therapeutics during the fourth quarter worth $74,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analysts Set New Price Targets

Separately, Wall Street Zen initiated coverage on shares of Revance Therapeutics in a report on Wednesday. They set a “hold” rating on the stock. Eight equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.45.

Revance Therapeutics Price Performance

Shares of NASDAQ RVNC opened at $3.65 on Friday. Revance Therapeutics, Inc. has a twelve month low of $2.30 and a twelve month high of $6.65. The firm has a fifty day simple moving average of $3.65 and a 200 day simple moving average of $3.61. The company has a market capitalization of $381.02 million, a PE ratio of -1.89 and a beta of 0.90.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.